Jardiance vs Lantus: Switching Between Empagliflozin and Insulin Glargine

How These Two Drugs Work Differently

Jardiance and Lantus attack hyperglycemia from opposite directions. Understanding these mechanisms is the foundation for any switching decision.

Empagliflozin (Jardiance) belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class. It blocks glucose reabsorption in the proximal tubule of the kidney, causing the body to excrete roughly 60-80 grams of glucose per day through urine 1. This mechanism works independently of insulin secretion, which means it does not rely on remaining beta-cell function. The caloric loss from glycosuria also produces modest weight reduction.

Insulin glargine (Lantus) is a long-acting basal insulin analog with a relatively flat pharmacokinetic profile lasting approximately 24 hours 2. It suppresses hepatic glucose output between meals and overnight. Unlike empagliflozin, it directly replaces or supplements endogenous insulin production, making it effective even in patients with minimal beta-cell reserve. The trade-off: exogenous insulin promotes lipogenesis and can cause weight gain, and dosing errors or missed meals create hypoglycemia risk.

These differences matter clinically. A patient with preserved beta-cell function, obesity, and established cardiovascular disease may benefit more from Jardiance. A patient with advanced type 2 diabetes who has already failed multiple oral agents, or whose fasting glucose remains above 200 mg/dL despite combination therapy, may need the glucose-lowering potency of basal insulin.

Cardiovascular and Renal Outcomes: What the Landmark Trials Show

The CV data separating these two drugs is substantial. It often drives the clinical decision to choose one over the other, or to switch.

EMPA-REG OUTCOME (N=7,020) randomized patients with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Over a median 3.1 years of follow-up, empagliflozin produced a 38% relative risk reduction in cardiovascular death (HR 0.62 to 95% CI 0.49-0.77, P<0.001) and a 35% reduction in hospitalization for heart failure 1. The separation in the CV death curves appeared within the first three months, suggesting a hemodynamic mechanism rather than a purely metabolic one.

The ORIGIN trial (N=12,537) tested a different question entirely. It randomized patients with early dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) to insulin glargine or standard care. After a median 6.2 years, there was no difference in cardiovascular events between groups (HR 1.02 to 95% CI 0.94-1.11) 2. The trial confirmed that early basal insulin neither increases nor decreases cardiovascular risk.

These are not competing results. They answer different questions in different populations. EMPA-REG enrolled high-risk patients with established CVD. ORIGIN enrolled lower-risk patients with early glucose abnormalities. No direct head-to-head trial compares empagliflozin and insulin glargine for cardiovascular outcomes.

The 2022 ADA/EASD consensus report positions SGLT2 inhibitors as preferred add-on therapy in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, independent of A1C 3. Basal insulin occupies a different slot: it is recommended when other agents cannot achieve glycemic targets, or when hyperglycemia is severe enough to warrant exogenous insulin coverage.

Dr. Silvio Inzucchi, co-author of the ADA/EASD consensus algorithm, has stated: "The choice between an SGLT2 inhibitor and insulin is not an either-or for many patients. SGLT2 inhibitors address cardiorenal risk. Insulin addresses glucose. Some patients need both" 3.

On renal outcomes, EMPA-REG showed a 39% reduction in incident or worsening nephropathy with empagliflozin (HR 0.61 to 95% CI 0.53-0.70) 1. This finding, later reinforced by the EMPA-KIDNEY trial, positioned empagliflozin as a renal-protective agent. Insulin glargine has no demonstrated renal benefit beyond what glycemic control itself provides 4.

A1C Reduction: Comparing Glucose-Lowering Potency

Lantus is the stronger glucose-lowering agent. That fact alone drives many switches.

In a pooled analysis of phase III empagliflozin trials, empagliflozin 25 mg reduced A1C by approximately 0.78% from a baseline of 7.9-8.1% when used as monotherapy 5. When added to metformin, the reduction was 0.64-0.77% depending on the study. The glucose-lowering effect of SGLT2 inhibitors diminishes as eGFR falls below 45 mL/min/1.73 m², because less glucose is filtered for the drug to block 6.

Insulin glargine, by contrast, has no ceiling on glucose-lowering potency. Dose-titrated to a fasting glucose target of 90-100 mg/dL, Lantus typically reduces A1C by 1.0-2.0% or more. In the Treat-to-Target trial, insulin glargine titrated to a fasting glucose of <100 mg/dL achieved a mean A1C of 6.96% from a baseline of 8.6%, a reduction of approximately 1.6% 7.

This gap matters for patients whose A1C sits above 9%. Jardiance alone is unlikely to bring such patients to the ADA target of <7%. Lantus, properly titrated, can. For patients closer to target (A1C 7.5-8.5%), Jardiance may provide sufficient reduction while adding cardiovascular and renal benefits that Lantus does not.

Weight and Metabolic Effects

The weight trajectories of these drugs move in opposite directions.

Empagliflozin consistently produces weight loss of 2-3 kg over 24-52 weeks in clinical trials, driven by the obligatory glycosuria (roughly 200-300 kcal/day excreted as glucose) and mild osmotic diuresis 5. This loss is primarily fat mass rather than lean mass, based on body composition sub-studies.

Insulin glargine causes weight gain averaging 1.6-3.0 kg over 6-12 months, with ongoing accumulation possible if doses escalate. The ORIGIN trial documented a mean weight gain of 1.6 kg over 6.2 years in the insulin glargine arm versus the standard care arm 2.

For patients already struggling with obesity (BMI >30), starting or switching to basal insulin can be psychologically discouraging and metabolically counterproductive if weight gain worsens insulin resistance. This is one of the most common reasons clinicians choose SGLT2 inhibitors or GLP-1 receptor agonists before initiating insulin.

The ADA Standards of Care (2024) specifically note that "weight effects should be considered when selecting glucose-lowering medications, particularly in patients with overweight or obesity" 8.

When to Switch from Jardiance to Lantus

The most common clinical scenario for this switch: Jardiance is not achieving adequate glycemic control.

Specific triggers include A1C remaining above individualized target (typically 7.0-7.5%) after 3-6 months on Jardiance plus metformin, fasting glucose consistently above 180 mg/dL suggesting significant beta-cell decline, or symptoms of hyperglycemia (polyuria, polydipsia, unintentional weight loss) indicating insulin deficiency 8.

When initiating Lantus after Jardiance, the standard approach is to start basal insulin at 10 units or 0.1-0.2 units/kg daily, injected once daily at a consistent time. Most clinicians continue empagliflozin when adding insulin, because the combination produces better glycemic control with less insulin-related weight gain than insulin alone. A 2018 trial showed that adding empagliflozin to basal insulin reduced A1C by an additional 0.6% while producing 1.7 kg weight loss versus placebo 9.

However, if the switch represents a full replacement (stopping Jardiance, starting Lantus), clinicians should be aware that the glycosuric effect of empagliflozin will wane over 2-3 days after discontinuation. Fasting glucose may rise during this transition window. Starting Lantus at the time of Jardiance discontinuation, rather than waiting, avoids a glycemic gap.

The 2022 ADA/EASD consensus report from Davies et al. recommends: "When basal insulin is needed, consider continuing the SGLT2 inhibitor for its cardiorenal benefits unless contraindicated" 3.

When to Switch from Lantus to Jardiance

This direction of switch is increasingly common. It happens for several reasons.

Patients on basal insulin who have achieved good fasting glucose control but want to reduce injection burden, avoid hypoglycemia, or address weight gain are candidates for transitioning to empagliflozin. This is only safe when the patient has sufficient endogenous insulin production to maintain glucose control without exogenous insulin.

Clinical markers suggesting a safe switch include: total daily insulin dose <0.5 units/kg, fasting C-peptide >1.0 ng/mL, no history of diabetic ketoacidosis, and diabetes duration <15 years 8. Patients with very low C-peptide levels or long-standing diabetes likely have insufficient beta-cell reserve to maintain glycemia without insulin.

The transition should be gradual. A common protocol reduces basal insulin by 20-30% at the time of empagliflozin initiation, then continues tapering over 2-4 weeks based on fasting glucose readings. Abrupt insulin discontinuation risks rebound hyperglycemia and, in rare cases, euglycemic diabetic ketoacidosis (euDKA), a known risk of SGLT2 inhibitors that is amplified when insulin is withdrawn too quickly 10.

Patients who are strong candidates for this switch: those with BMI >30, established cardiovascular disease or heart failure (to gain the CV benefits of empagliflozin), preserved renal function (eGFR >30 mL/min), and motivation to reduce injectable medications.

Safety Profiles: Side-by-Side

Each drug carries a distinct adverse-event signature.

Jardiance's primary safety concerns include genital mycotic infections (occurring in 5-11% of women and 1-5% of men), urinary tract infections, volume depletion in elderly or diuretic-treated patients, and the rare but serious risk of euglycemic DKA 6. The FDA issued a warning in 2015 about SGLT2 inhibitor-associated ketoacidosis, which can present with near-normal glucose levels, making it easy to miss. Patients who are acutely ill, fasting, or have reduced carbohydrate intake are at higher risk.

Lantus's primary safety concern is hypoglycemia. In the Treat-to-Target study, confirmed symptomatic hypoglycemia (blood glucose <56 mg/dL) occurred in 33% of glargine-treated patients over 24 weeks when titrated to a fasting glucose target <100 mg/dL 7. Weight gain, injection-site reactions, and the logistical burden of daily injections and glucose monitoring are additional considerations.

The hypoglycemia contrast is stark. SGLT2 inhibitors have a glucose-dependent mechanism: once blood glucose normalizes, the kidneys have less glucose to excrete, creating a natural floor. Insulin has no such floor. It will continue to lower glucose regardless of the starting level. This difference makes Jardiance substantially safer for patients at risk of severe hypoglycemia, including the elderly and those living alone.

Cost and Insurance Considerations

Both drugs are expensive without coverage. The choice sometimes depends on which one the patient can actually afford.

Jardiance's wholesale acquisition cost is approximately $550-600 per month for either the 10 mg or 25 mg tablet. Boehringer Ingelheim offers a savings card that can reduce copays for commercially insured patients 11. Generic empagliflozin is not yet widely available in the US as of early 2026.

Lantus's patent has expired, and biosimilar insulin glargine products (Semglee, Rezvoglar, insulin glargine-yfgn) are available. These biosimilars cost 40-65% less than branded Lantus. Even branded Lantus has manufacturer discount programs. For patients without insurance or with high-deductible plans, the availability of biosimilar glargine often makes insulin the more affordable option 12.

The Inflation Reduction Act capped insulin copays at $35 per month for Medicare beneficiaries beginning in 2023, which substantially changed the cost calculus for Medicare patients considering basal insulin. This cap does not apply to SGLT2 inhibitors 8.

Combining Jardiance and Lantus Together

For many patients, the answer is not either-or. It is both.

The ADA treatment algorithm places SGLT2 inhibitors alongside basal insulin as complementary agents. Adding empagliflozin to a patient already on insulin glargine provides three benefits: additional A1C reduction (0.5-0.7%), weight mitigation against insulin-related gain, and cardiorenal protection 3.

When combining, insulin doses often need a 10-20% reduction to avoid hypoglycemia, since empagliflozin will lower glucose independently. Volume status should be monitored for the first 2-4 weeks, especially in patients also taking loop diuretics or ACE inhibitors. The euDKA risk, while low, is highest in patients on insulin who have doses reduced aggressively after starting an SGLT2 inhibitor.

The EASE trials (Empagliflozin as Adjunctive to Insulin Therapy) demonstrated that even in type 1 diabetes (an off-label context), adding empagliflozin to insulin reduced A1C and weight, though at the cost of increased DKA risk 13. In type 2 diabetes, the combination is well-established and supported by guidelines.